катехоламинергия调节对干扰控制的剂量依赖性影响:基线GABA和Glx在皮层-皮下网络中的作用
Anna Helin Koyun1,2, Annett Werner3, Paul Kuntke3
1Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine, TU Dresden, Dresden, Germany.
Human brain mapping
|October 23, 2025
概括
甲基化物 (MPH) 剂量通过改变神经递质,影响认知控制. 较高的MPH剂量改善了冲突解决,大脑活动根据大脑关键区域的剂量和神经递质水平而变化.
科学领域:
- 神经科学是一个神经科学.
- 认知心理学 认知心理学
- 神经成像是一种神经成像.
背景情况:
- 认知控制对于以目标为导向的行为至关重要,涉及由皮层-亚皮层电路中神经递质相互作用影响的冲突解决.
- 了解氨基酸传递器和 катехоламинер基系统之间的相互作用对于阐明干扰控制机制至关重要.
研究的目的:
- 为了研究基线氨基酸传递体水平 (GABA+,Glx) 和干扰控制之间的关系.
- 通过实验增强甲基酸盐 (MPH) 增强神经质信号传递对认知控制和神经生理学的影响.
主要方法:
- 质子磁共振光谱 (1H-MRS) 用于测量71名健康成年人前扣带皮层 (ACC),条纹体和补充运动区域 (SMA) 的基线GABA+和Glx水平.
- 一个双盲,安慰剂控制的交叉设计评估了在安慰剂和两个剂量MPH (0.25 mg/kg和0.50 mg/kg) 下的潜面预备侧面任务的性能.
- 在任务期间记录了脑电图 (EEG),以分析神经生理反应,包括甲频段活动 (TBA) 和α频段活动 (ABA).
主要成果:
- 与低剂量 (0.25 mg/kg) 相比,中等MPH剂量 (0.50 mg/kg) 显著降低了潜意识干扰效应,显示出剂量特定的行为改善.
- 基线条状GABA+水平与低剂量MPH更好的干扰控制相关,而较低的ACC GABA+和GABA+/Glx比率与中等剂量MPH更好的控制有关.
- 脑电图数据显示,在高度认知控制要求下,前线集群中TBA和ABA增加,这表明冲突解决的神经相关性.
结论:
- 基线氨基酸发射剂水平在调节干扰控制中的有效性取决于 катехоламин的信号传输水平,显示了大脑区域主导的剂量依赖转变 (从条形状到ACC).
- 甲基胺对认知控制的增强是剂量依赖的,并与内源性氨基酸传递系统相互作用.
- 神经生理学发现支持前端和α活动在由MPH调节的认知控制过程中的作用.
关键词:
在GABA+的基础上,GABA+Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx这就是MRS MRS.类甲基胺 (Catecholamines) 是一种类甲基胺.干扰控制 干扰控制更多相关视频
14:47Author Spotlight: Combined Peripheral Nerve Stimulation and Controllable Pulse Parameter Transcranial Magnetic Stimulation to Probe Sensorimotor Control and Learning
Published on: April 21, 2023
3.7K
10:53Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method
Published on: February 26, 2018
48.3K
相关概念视频
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.6K
01:23Drugs Acting on Autonomic Ganglia: Stimulants
2.0K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.0K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K